The Seattle-based company came to ASCO25 with new data on its neuroendocrine tumor–treating lead therapy, with big vibes and ...

Novartis and Amgen also boast impeccable dividend track records, which should please investors. When broader equities are ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

QINT offers diversified exposure to international equities, with strong representation from innovative and market-leading ...

As a leader in its category, Sinotau is probably hoping to follow in the footsteps of Hengrui Pharmaceuticals (1276.HK; ...

The PSMAddition trial shows 177Lu PSMA-617 significantly delays progression in mHSPC when added to hormone therapy, with a ...

Novartis admitted the email broke several rules set out in the U.K. marketing code. In a long response to the PMCPA, the ...

The next big test is whether using Pluvicto can delay the advancement of prostate cancer enough to delay chemical castration, ...

The American Society for Clinical Oncology’s Annual Meeting for 2025 is, if nothing else, absolutely overwhelming and ...

Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified interim analysis of Pluvicto.

Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive mHSPC: Basel Tuesday, June 3, 2025, 12:00 Hrs [IST] ...

Novartis (NYSE:NVS) announced positive topline results from the Phase III PSMAddition trial, which showed that its targeted ...